blrx stock forecast zacks

Our Financial Advisors Offer a Wealth of Knowledge. Learn more on BLRXs analyst rating history.

NASDAQBLRX reported 2021 operational and financial results in a press release concurrent with the filing of Form 20-FA conference call and webcast was hosted later that morning.

. 100 the week before that will be reflected as a. By John Vandermosten CFA. Click here - the BLRX analysis is free About Price and.

BioLineRx last issued its quarterly earnings data on March 16th 2022. Shares of BioLineRx stock opened at 154 on. If a stocks EPS consensus estimate is 110 now vs.

We are initiating on BioLineRx Ltd. According to the issued ratings of 1 analysts in the last year the consensus rating for BioLineRx stock is Buy based on the current 1 buy rating for BLRX. READ THE FULL BLRX RESEARCH REPORT.

Find a Dedicated Financial Advisor Now. READ THE FULL BLRX RESEARCH REPORT. BLRX Earnings Information.

Full Year 2021 Operational and Financial Results. View analysts price targets for BioLineRx or view top-rated stocks among Wall Street analysts. ARCO is reporting for the quarter ending.

Zacks Investment Research is releasing its prediction for BLRX based on the 1-3 month trading system that nearly triples the SP 500. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. This suggests a possible upside of 5098 from the stocks current price.

BLRX Quick Quote BLRX Negative Net Change FLXN Quick Quote FLXN Positive Net Change. NASDAQBLRX Get Rating to post earnings of 015 per share for the current quarter Zacks. Ad Experts trust Zacks research.

Finance Forbes and others. The biotechnology company reported 008 EPS for the quarter beating analysts consensus estimates of 014 by 006. Searching for Financial Security.

Youll find the Bioline Rx Ltd - ADR share forecasts stock quote and buy sell signals belowAccording to present data Bioline Rx Ltd - ADRs BLRX shares and potentially its market environment have been in bearish. BioLineRx has generated 073 earnings per share over the last year 073 diluted earnings per share. By John Vandermosten CFA.

Wall Street Stock Market Finance report prediction for the future. Its an integral part of the Zacks Rank and a critical part in effective stock evaluation. Ad Ensure Your Investments Align with Your Goals.

The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 1000 with a high estimate of 1900 and a low estimate of 725. 11 Wall Street analysts have issued twelve-month target prices for BioCryst Pharmaceuticals stock. Zacks Investment Research reports that the 2022 Price to Earnings ratio for JBL is 950 vs.

Buy or sell Bioline Rx Ltd - ADR stock. NASDAQ Updated Apr 14 2022 810 PM BLRX 154 001 065. Equities research analysts expect BioLineRx Ltd.

NASDAQBLRX Get Rating will post earnings of 015 per share for the current quarter according to Zacks Investment ResearchZero analysts. ASLN BLRX FLXN ICMB and MRNS have been added to the Zacks Rank 5 Strong Sell List on June 4 2021. On March 16 2022 BioLineRx Ltd.

This suggests a possible upside of 748 from the stocks current price. An industry ratio of 1110. Since 1988 it has more than doubled the SP 500 with an average gain of.

Find real-time BLRX - BioLine RX Ltd stock quotes company profile news and forecasts from CNN Business. The average twelve-month price target for BioLineRx is 1000 with a high price target of 1000 and a low price target of 1000. Check out Zacks stock rank on your favorite tickers today absolutely FREE.

On average they anticipate BioCryst Pharmaceuticals stock price to reach 1991 in the next year. Arcos Dorados Holdings Inc. Bioline Rx Ltd - ADR Stock Market info Recommendations.

Their forecasts range from 1400 to 3000. Equities analysts forecast that BioLineRx Ltd. NASDAQBLRX Get Rating will post earnings per share EPS of 015 for the current.

Wall Street analysts forecast that BioLineRx Ltd. Its used by Nasdaq Yahoo. Their forecasts range from 1000 to 1000.

On average they expect BioLineRxs stock price to reach 1000 in the next year. BioLineRx BLRX has been upgraded to a Zacks Rank 2 Buy reflecting growing optimism about the companys earnings prospects. NASDAQBLRX with our valuation based on the companys progress advancing Motixafortide for the mobilization of hematopoietic stem cells HSCs for autologous transplantation in subjects with multiple myeloma MM.

Biolinerx Ltd Blrx Stock Price Quote News Stock Analysis